Drug Approval | April 09, 2025
Shilpa’s Unit-2 passes second consecutive FDA inspection with no 483s
Raichur site is the group’s largest API facility and part of a wider network of seven sites
Raichur site is the group’s largest API facility and part of a wider network of seven sites
This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets
Introduces revolutionary approach to workflow management to enhance operational efficiency and optimize process efficiency
Asahi Kasei Life Science covers a broad range of bioprocess products and services
In light of the contributions of these three institutes, it was decided to organize a CSIR Startup Conclave in Hyderabad. The event, scheduled for April 22–23, 2025
Findings likely to generate hypotheses about potential new uses of drugs
Increases Siemens’ industrial software total addressable market by $11 billion; aligns with strategic goal to accelerate customer innovation across industries
The portfolio includes branded injectable cephalosporines for infectious diseases
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
Subscribe To Our Newsletter & Stay Updated
